• Consensus Rating: Buy
  • Consensus Price Target: $118.33
  • Forecasted Upside: 46.42 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$80.82
▲ +3.04 (3.91%)

This chart shows the closing price for CNMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CONMED Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CNMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CNMD

Analyst Price Target is $118.33
▲ +46.42% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for CONMED in the last 3 months. The average price target is $118.33, with a high forecast of $127.00 and a low forecast of $110.00. The average price target represents a 46.42% upside from the last price of $80.82.

This chart shows the closing price for CNMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in CONMED. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/6/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/5/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/3/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/1/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/30/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/29/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/28/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/28/2022Needham & Company LLCLower TargetBuy$155.00 ➝ $127.00Low
7/28/2022Piper SandlerLower TargetOverweight$160.00 ➝ $118.00Low
6/23/2022Stifel NicolausLower TargetBuy$160.00 ➝ $110.00Low
3/2/2022Bank of AmericaInitiated CoverageNeutral ➝ NeutralLow
1/21/2022Needham & Company LLCLower TargetBuy$158.00 ➝ $150.00High
10/28/2021Needham & Company LLCBoost TargetBuy$150.00 ➝ $158.00High
10/6/2021Needham & Company LLCUpgradeHold ➝ Buy$150.00High
7/15/2021UBS GroupInitiated CoverageBuy$160.00High
5/24/2021BarclaysInitiated CoverageOverweight$175.00Low
4/29/2021Piper SandlerBoost TargetPositive ➝ Overweight$145.00 ➝ $160.00High
1/28/2021Piper SandlerBoost TargetOverweight$95.00 ➝ $145.00Low
7/30/2020Stifel NicolausBoost TargetBuy$82.00 ➝ $100.00High
7/30/2020SVB LeerinkBoost TargetMarket Perform$82.00 ➝ $92.00High
7/29/2020Piper SandlerBoost TargetOverweight$90.00 ➝ $95.00Medium
4/30/2020SVB LeerinkReiterated RatingMarket PerformLow
4/30/2020Stifel NicolausBoost TargetBuy$65.00 ➝ $82.00Medium
4/30/2020Piper SandlerLower TargetOverweight$110.00 ➝ $90.00Medium
4/30/2020Needham & Company LLCReiterated RatingHoldMedium
4/23/2020JPMorgan Chase & Co.Lower TargetOverweight$136.00 ➝ $76.00Medium
4/14/2020BarclaysReiterated RatingBuy$110.00Medium
3/10/2020Piper SandlerLower Target$130.00 ➝ $110.00High
3/10/2020Needham & Company LLCReiterated RatingHoldHigh
11/26/2019Needham & Company LLCDowngradeBuy ➝ HoldHigh
11/12/2019JPMorgan Chase & Co.Initiated CoverageOverweight$136.00Medium
10/31/2019Needham & Company LLCBoost TargetBuy$111.00 ➝ $115.00High
10/4/2019Needham & Company LLCBoost TargetBuy$101.00 ➝ $111.00Medium
8/22/2019Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$88.00 ➝ $110.00High
8/1/2019Stifel NicolausBoost TargetBuy$97.00 ➝ $99.00High
8/1/2019BarclaysBoost TargetOverweight$96.00 ➝ $105.00High
4/17/2019Stifel NicolausInitiated CoverageBuy ➝ Buy$95.00Medium
4/16/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$87.00 ➝ $94.00High
4/15/2019BarclaysBoost TargetOverweight ➝ Overweight$85.00 ➝ $92.00Low
2/27/2019Needham & Company LLCBoost TargetBuy$87.00Low
2/19/2019BarclaysInitiated CoverageEqual Weight ➝ Overweight$85.00High
1/23/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$86.00 ➝ $79.00High
10/16/2018BarclaysSet TargetEqual Weight ➝ Equal Weight$78.00High
8/30/2018SVB LeerinkBoost TargetMarket Perform$76.00 ➝ $81.00Low
8/2/2018Needham & Company LLCBoost TargetBuy$73.00 ➝ $83.00High
4/26/2018Needham & Company LLCBoost TargetBuy ➝ Buy$71.00 ➝ $73.00High
2/1/2018Needham & Company LLCBoost TargetBuy ➝ Buy$58.00 ➝ $71.00High
11/17/2017Needham & Company LLCReiterated RatingBuy$58.00N/A
11/3/2017KeyCorpReiterated RatingHoldN/A
11/3/2017Piper Jaffray CompaniesReiterated RatingHold$46.00N/A
(Data available from 9/28/2017 forward)

News Sentiment Rating

0.38 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/2/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/1/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/1/2022
  • 5 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2022
  • 3 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/30/2022
  • 1 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2022
  • 2 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
8/29/2022
  • 3 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2022

Current Sentiment

  • 3 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
CONMED logo
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
Read More

Today's Range

Now: $80.82
Low: $77.24
High: $81.06

50 Day Range

MA: $94.16
Low: $77.78
High: $103.21

52 Week Range

Now: $80.82
Low: $77.09
High: $159.11

Volume

411,310 shs

Average Volume

363,166 shs

Market Capitalization

$2.46 billion

P/E Ratio

N/A

Dividend Yield

1.03%

Beta

1.5

Frequently Asked Questions

What sell-side analysts currently cover shares of CONMED?

The following Wall Street sell-side analysts have issued research reports on CONMED in the last twelve months: Bank of America Co., Needham & Company LLC, Piper Sandler, Stifel Nicolaus, StockNews.com, and TheStreet.
View the latest analyst ratings for CNMD.

What is the current price target for CONMED?

3 Wall Street analysts have set twelve-month price targets for CONMED in the last year. Their average twelve-month price target is $118.33, suggesting a possible upside of 48.9%. Needham & Company LLC has the highest price target set, predicting CNMD will reach $127.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $110.00 for CONMED in the next year.
View the latest price targets for CNMD.

What is the current consensus analyst rating for CONMED?

CONMED currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CNMD will outperform the market and that investors should add to their positions of CONMED.
View the latest ratings for CNMD.

What other companies compete with CONMED?

How do I contact CONMED's investor relations team?

CONMED's physical mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The company's listed phone number is (727) 392-6464. The official website for CONMED is www.conmed.com. Learn More about contacing CONMED investor relations.